SG195191A1 - Methods and compositions of predicting activity of retinoid x receptor modulator - Google Patents

Methods and compositions of predicting activity of retinoid x receptor modulator

Info

Publication number
SG195191A1
SG195191A1 SG2013087861A SG2013087861A SG195191A1 SG 195191 A1 SG195191 A1 SG 195191A1 SG 2013087861 A SG2013087861 A SG 2013087861A SG 2013087861 A SG2013087861 A SG 2013087861A SG 195191 A1 SG195191 A1 SG 195191A1
Authority
SG
Singapore
Prior art keywords
receptor modulator
retinoid
compositions
methods
biomarkers
Prior art date
Application number
SG2013087861A
Other languages
English (en)
Inventor
Wen Lou
Original Assignee
Denovo Biopharma Hangzhou Ltd Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denovo Biopharma Hangzhou Ltd Co filed Critical Denovo Biopharma Hangzhou Ltd Co
Publication of SG195191A1 publication Critical patent/SG195191A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/30Prediction of properties of chemical compounds, compositions or mixtures
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
SG2013087861A 2011-06-08 2012-06-07 Methods and compositions of predicting activity of retinoid x receptor modulator SG195191A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161494773P 2011-06-08 2011-06-08
PCT/US2012/041379 WO2012170704A2 (en) 2011-06-08 2012-06-07 Methods and compositions of predicting activity of retinoid x receptor modulator

Publications (1)

Publication Number Publication Date
SG195191A1 true SG195191A1 (en) 2013-12-30

Family

ID=47296742

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013087861A SG195191A1 (en) 2011-06-08 2012-06-07 Methods and compositions of predicting activity of retinoid x receptor modulator

Country Status (12)

Country Link
US (1) US10202652B2 (https=)
EP (1) EP2718486A4 (https=)
JP (1) JP2014524735A (https=)
KR (1) KR20140039278A (https=)
CN (1) CN103649386B (https=)
AU (1) AU2012267877B2 (https=)
BR (1) BR112013031221A2 (https=)
CA (1) CA2838207A1 (https=)
MX (1) MX2013014437A (https=)
RU (1) RU2013158861A (https=)
SG (1) SG195191A1 (https=)
WO (1) WO2012170704A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US11089959B2 (en) * 2013-03-15 2021-08-17 I2Dx, Inc. Electronic delivery of information in personalized medicine
US9782075B2 (en) * 2013-03-15 2017-10-10 I2Dx, Inc. Electronic delivery of information in personalized medicine
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
WO2015073896A2 (en) * 2013-11-15 2015-05-21 Psma Development Company, Llc Biomarkers for psma targeted therapy for prostate cancer
PT3097122T (pt) 2014-01-24 2020-07-21 Ngm Biopharmaceuticals Inc Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN104131102B (zh) * 2014-08-07 2016-06-15 马飞 一种判断nsclc患者对吉非替尼治疗反应性的试剂盒
CN114129709A (zh) 2014-10-23 2022-03-04 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド 胆汁酸に関係した障害の治療方法
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين
WO2019044852A1 (ja) * 2017-08-31 2019-03-07 株式会社資生堂 レチノイドの副作用に対する感受性の決定方法
CN108504733A (zh) * 2017-11-29 2018-09-07 中山拓普基因科技有限公司 肿瘤个体化化疗用药指导基因snp位点检测组合物
KR102169699B1 (ko) * 2019-12-27 2020-10-23 주식회사 클리노믹스 유전자 검사를 위한 맞춤형 유전자칩 및 이의 제작 방법
EP4106872A4 (en) 2020-03-06 2024-04-10 Denovo Biopharma LLC Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters
KR20250118433A (ko) * 2024-01-30 2025-08-06 서울대학교산학협력단 알츠하이머병 발병 위험도 예측을 위한 레이 복잡도 복사 점수 저하와 관련이 있는 단일염기다형성 마커 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280955A1 (en) * 2005-09-30 2008-11-13 Perlegen Sciences, Inc. Methods and compositions for screening and treatment of disorders of blood glucose regulation
BRPI0616454A2 (pt) * 2005-09-30 2011-06-21 Vitae Pharmaceuticals, Inc. métodos de tratamento de cáncer
WO2007145992A2 (en) 2006-06-05 2007-12-21 Perlegen Sciences, Inc. Genetic basis of treatment response in depression patients
WO2009134774A1 (en) 2008-04-28 2009-11-05 Expression Analysis Methods and systems for simultaneous allelic contrast and copy number association in genome-wide association studies
US20120115912A1 (en) 2009-07-10 2012-05-10 Landreth Gary E Rxr agonist compounds and methods
CA2779223A1 (en) * 2009-10-27 2011-05-12 Caris Mpi, Inc. Molecular profiling for personalized medicine
US7790396B1 (en) 2009-12-23 2010-09-07 Suregene, Llc Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype

Also Published As

Publication number Publication date
US20150368720A1 (en) 2015-12-24
KR20140039278A (ko) 2014-04-01
AU2012267877B2 (en) 2015-12-24
CN103649386A (zh) 2014-03-19
US10202652B2 (en) 2019-02-12
RU2013158861A (ru) 2015-07-20
BR112013031221A2 (pt) 2017-01-24
CN103649386B (zh) 2015-12-23
EP2718486A4 (en) 2014-12-31
JP2014524735A (ja) 2014-09-25
AU2012267877A1 (en) 2014-01-23
WO2012170704A3 (en) 2013-01-31
MX2013014437A (es) 2015-03-20
EP2718486A2 (en) 2014-04-16
CA2838207A1 (en) 2012-12-13
WO2012170704A2 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
SG195191A1 (en) Methods and compositions of predicting activity of retinoid x receptor modulator
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
PH12019500422A1 (en) Methods and composition for the prediction of the activity of enzastaurin
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
BR112012020101A2 (pt) método diagnósticos e terapêuticos usando anticorpos anti-cd200.
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
PH12014501106B1 (en) Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
MY167920A (en) HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
MX2020002867A (es) Inhibidores de glucosilceramida sintasa.
UA118248C2 (uk) Інгібітори глюкозилцерамідсинтази
NZ707139A (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
MX2022004300A (es) Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2018008882A (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
HK1207953A1 (en) An enhanced therapeutic stimulus system and methods of use
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
PH12015502687A1 (en) Marker for acid sphingomyelinase disorders and uses thereof
MX2014005749A (es) Nanoportadores terapeuticos y/o de diagnostico, dirigidos a metaloproteinasa de matriz (mmp).
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
WO2012109233A3 (en) Methods for predicting recurrence risk in breast cancer patients
EP4241677A3 (en) System for predictive neurodevelopment therapy for oral feeding
MX351945B (es) Mutantes c-raf que confieren resistencia a inhibidores raf.
BR112012028409A2 (pt) método para produzir pleurodese em um sujeito mamífero e kit.
HK1196648A (en) Methods and compositions of predicting activity of retinoid x receptor modulator
BR112014019274A2 (pt) métodos relacionados ao tratamento de doenças e distúrbios inflamatórios